陕西康惠制药股份有限公司2025年半年度业绩预告

Group 1 - The company expects a net profit attributable to shareholders of approximately -38 million yuan for the first half of 2025, indicating a loss [2][4] - The estimated net profit attributable to shareholders, excluding non-recurring gains and losses, is approximately -41 million yuan for the same period [5] - The performance forecast period is from January 1, 2025, to June 30, 2025 [3] Group 2 - For the first half of 2024, the total profit was -9.88 million yuan, with a net profit attributable to shareholders of -8.70 million yuan [7] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -15.99 million yuan [7] - The earnings per share for the first half of 2024 was -0.09 yuan [8] Group 3 - The primary reasons for the expected loss include increased costs and expenses due to changes in pharmaceutical policies and industry environment [9] - The company is actively adjusting its business strategy to focus on sales and expand its market presence in community hospitals, clinics, and pharmacies [9] - The subsidiary, Shaanxi Youbang Biomedical Technology Co., Ltd., is experiencing significant depreciation and financing costs, along with unfavorable market conditions, contributing to the overall loss [9] Group 4 - The company has received a civil appeal regarding a lawsuit related to a share repurchase agreement, with the amount involved being approximately 37.99 million yuan plus interest [16] - The company is currently in the stage of receiving the appeal, and the outcome of the lawsuit remains uncertain [14][16] - The company will fulfill its information disclosure obligations based on the progress of the lawsuit [16]